BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 301–400 of 894
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Zhai, Y., Moosavi, R., & Chen, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645699 · Cited by 49
“The knockout of the BTLA receptor triggers experimental autoimmune encephalitis (EAE), a murine version of MS (23).”
BackgroundCellular Immunotherapy of Cancer
Okur, F. V., & Brenner, M. K. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-786-0_19 · Cited by 48
Hazrati, A., Malekpour, K., Khorramdelazad, H., Rajaei, S., & Hashemi, S. M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00580-2 · Cited by 47
“BTLA has been identified as the third immune checkpoint after PD-1 and CTLA-4, and having 2 ITIM motifs leads to the calling of SHP2, which inhibits signaling events related to inflammatory responses [250, 251].”
BackgroundCoinhibitory Molecules in Autoimmune Diseases
Watanabe, N., & Nakajima, H. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/269756 · Cited by 45
“B and T lymphocyte attenuator (BTLA), the third coinhibitory molecule for T-cell activation, is a cell surface molecule with similarities to CTLA-4 and PD1 [5].”
InfluentialSelf-citationBoliar, S., Murphy, M. K., Tran, T. C., Carnathan, D. G., Armstrong, W. S., Silvestri, G., & Derdeyn, C. A. (2012) · Journal of Virology · doi:10.1128/jvi.00771-12 · Cited by 48
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
Speiser, D. E., & Romero, P. J. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.004 · Cited by 55
A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis
Fallon, E. A., Girard, B., Chung, C., Lomas‐Neira, J., Heffernan, D. S., Monaghan, S. F., & Ayala, A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0917-377r · Cited by 46
Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins
Yang, Q., Cao, W., Wang, Z., Zhang, B., & Liu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.015 · Cited by 46
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
“B and T lymphocyte attenuator (BTLA) is yet another receptor in the Ig supergene family [153] that is expressed not only by naïve and activated B- and T-cells but also by monocytes and DCs [154].”
BackgroundModulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity
Biber, G., Sabag, B., Raiff, A., Ben‐Shmuel, A., Puthenveetil, A., Benichou, J. I. C., Jubany, T., Levy, M., Killner, S., & Barda‐Saad, M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114073 · Cited by 46
“…inhibitory receptors expressed on NK cells, since SHP-1 and Cbls inhibit NK cell activation downstream to multiple inhibitory checkpoint receptors such as PD-1 (Chemnitz et al , 2004), TIGIT (Dougall et al , 2017), BTLA, CEACAM, TIM-3, LAG-3, and others (Watanabe et al , 2003; Torphy et al , 2017).”
The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases
Wojciechowicz, K., Spodzieja, M., Lisowska, K. A., & Wardowska, A. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104532 · Cited by 49
BTNL8, a butyrophilin-like molecule that costimulates the primary immune response
Chapoval, A. I., Smithson, G. M., Brunick, L., Mesri, M., Boldog, F. L., Andrew, D. P., Khramtsov, N. V., Feshchenko, E. A., Starling, G. C., & Mézeš, P. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.08.003 · Cited by 48
Salmond, R. J., Huyer, G., Kotsoni, A., Clements, L. A., & Alexander, D. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6498 · Cited by 48
“However, SHP2 may be involved in inhibitory signaling by receptors such as the B and T lymphocyte attenuator, which is induced on T cells following activation (41).”
BackgroundModulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy
Castro-Sanchez, P., Teagle, A. R., Prade, S., & Zamoyska, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608747 · Cited by 44
“Results showed that, consistent with a previous report (Watanabe et al., 2003), both SHP-1 and SHP-2 bind BTLA.”
ResultNovel antibodies targeting immune regulatory checkpoints for cancer therapy
Lee, C. S., Cragg, M. S., Glennie, M. J., & Johnson, P. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12164 · Cited by 46
Lei, G.-S., Zhang, C., & Lee, C. (2014) · Infection and Immunity · doi:10.1128/iai.02686-14 · Cited by 48
Suppression of Human T-Cell Responses to β-Cells by Activation of B7-H4 Pathway
Ou, D., Wang, X., Metzger, D. L., Ao, Z., Pozzilli, P., James, R. F. L., Chen, L., & Warnock, G. L. (2006) · Cell Transplantation · doi:10.3727/000000006783981837 · Cited by 44
Sugita, S., Ng, T. F., Schwartzkopff, J., & Streilein, J. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4184 · Cited by 45
Combination of targeted therapy and immunotherapy in melanoma
Blank, C. U., Hooijkaas, A. I., Haanen, J. B. A. G., & Schumacher, T. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1079-2 · Cited by 54
“constitutively expressed on tumor-speciWc T cells, inhibiting T cells functions [56].”
BackgroundGe, J., Zhu, L., Zhou, J., Li, G., Li, Y., Li, S., Wu, Z., Rong, J., Yuan, H., Liu, Y., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1915-4 · Cited by 43
Structural Basis of CD160:HVEM Recognition
Liu, W., Garrett-Thomson, S. C., Fedorov, E. V., Ramagopal, U. A., Garforth, S., Bonanno, J. B., & Almo, S. C. (2019) · Structure · doi:10.1016/j.str.2019.05.010 · Cited by 44
“In contrast to the costimulatory function of the LIGHT:HVEM trans interaction, BTLA engagement by HVEM delivers a coinhibitory signal to attenuate CD4 T cell activation similar to the CTLA-4 and PD-1 receptor systems (Sedy et al., 2005, 2017; Watanabe et al., 2003) (Figure 1).”
BackgroundCostimulation blockade: towards clinical application
Timothy, A. W. (2007) · Frontiers in bioscience · doi:10.2741/2829 · Cited by 47
“It also regulates peripheral T cell tolerance, binding to CD80 and CD86, and inducing expression of idoleamine 2,3 dioxygenase (IDO) in DCs (42).”
BackgroundInfluentialAssociation of a BTLA gene polymorphism with the risk of rheumatoid arthritis
Lin, S., Kuo, C., & Chan, C.-H. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-006-9113-7 · Cited by 44
“The inhibitory signal of BTLA appears to be mediated by the recruitment of SHP-1 and SHP-2 to two immuno-receptor tyrosine inhibitory motifs (ITIMs) in the cytoplasmic region of BTLA [4, 5].”
BackgroundInfluentialAkt Is a Neutral Amplifier for Th Cell Differentiation
Arimura, Y., 白木, 文., Kuwahara, S., Kato, H., Dianzani, U., Uchiyama, T., & Yagi, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309063200 · Cited by 44
The role of the T follicular helper cells in allergic disease
Kemeny, D. M. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.31 · Cited by 47
Zhang, L., Wang, J., Wei, F., Wang, K., Sun, Q., Yang, F., Jin, H., Zheng, Y., Zhao, H., Wang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9871 · Cited by 44
“BTLA was identified as another inhibitory molecule that has structural similarities with CTLA-4 and PD-1 [21].”
InfluentialComprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer
Xu, Z., Shen, J., Wang, M. H., Yi, T., Yu, Y., Zhu, Y., Chen, B., Chen, J., Li, L., Li, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1207841 · Cited by 44
“Using the network derived from cBioPortal, which consists of pathways and interactions from several databases, we identified BTLA as a putative receptor for B7-H4, which is consistent with a previous report.(41) Moreover, BTLA is co-expressed with certain B7 family members including B7H4.”
MethodPodojil, J. R., Chiang, M.-Y., Ifergan, I., Copeland, R. J., Liu, L. N., Maloveste, S. M., Langermann, S., Liebenson, D., Balabanov, R. D., Chi, H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700811 · Cited by 43
Kojima, R., Kajikawa, M., Shiroishi, M., Kuroki, K., & Maenaka, K. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.09.018 · Cited by 45
Sekar, D., Govene, L., del Rio, M., Sirait‐Fischer, E., Fink, A. F., Brüne, B., Rodríguez-Barbosa, J.-I., & Weigert, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030752 · Cited by 45
“Upon activation, BTLA expression on B cells decreases, while it increases on T cells, especially on Th1 cells [3,6].”
BackgroundYang, C., Chen, Y., Guo, G., Li, H., Cao, D., Xu, H., Guo, S., Fei, L., Yan, W., Ning, Q., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302239 · Cited by 41
Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
Kamali, A. N., Bautista, J. M., Eisenhut, M., & Hamedifar, H. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231192043 · Cited by 53
Yuan, B., Zhao, L. B., Fu, F., Liu, Y., Lin, C., Wu, X., Shen, H., & Zhao, Y. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.08.006 · Cited by 45
Sasso, E., D’Avino, C., Passariello, M., D’Alise, A. M., Siciliano, D., Esposito, M. L., Froechlich, G., Cortese, R., Scarselli, E., Zambrano, N., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1496772 · Cited by 47
“CD8 cancer-specific T cells.(12) Like PD-1 and CTLA-4, BTLA interacts with a B7 homolog, B7H4, but unlike PD-1 and CTLA-4, BTLA displays T cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors.”
BackgroundCD160 serves as a negative regulator of NKT cells in acute hepatic injury
Kim, T.-J., Park, G., Kim, J., Lim, S. A., Kim, J., Im, K., Shin, M. H., Fu, Y., del Rio, M., Rodríguez-Barbosa, J.-I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10320-y · Cited by 43
The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer
Chen, S., Wang, S.-C., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312836 · Cited by 44
“A similar inhibition reaction is also found in CTLA-4 receptors on T cells, and other potential targets, such as B and T lymphocyte attenuator (BTLAs) [4], the variable domain immunoglobin suppressor of T cell activation (VISTA), the T cell immunoglobulin and mucin-containing protein 3 (TIM3), the lymphocyte-activated…”
MethodDefective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells
Sawaf, M., Fauny, J., Felten, R., Sagez, F., Gottenberg, J., Dumortier, H., & Monneaux, F. (2018) · JCI Insight · doi:10.1172/jci.insight.99711 · Cited by 44
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
Aubert, N., Brunel, S., Olive, D., & Marodon, G. (2021) · Cancers · doi:10.3390/cancers13123009 · Cited by 43
“HVEM signaling through BTLA inhibits T cell activation through recruitment of Srchomology domain 2-containing protein tyrosine phosphatases, SHP-1, and SHP-2 to the phosphorylated tyrosines of immunoreceptor tyrosine-based inhibitory motif [9].”
BackgroundOki, M., Watanabe, N., Owada, T., Oya, Y., Ikeda, K., Saito, Y., Matsumura, R., Seto, Y., Iwamoto, I., & Nakajima, H. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/305656 · Cited by 42
“Ligation of BTLA induces its tyrosine phosphorylation and SHP-1/SHP-2 association and then attenuates IL-2 production and proliferation of T cells [16, 21].”
BackgroundInfluentialSelf-citationMolecular Insights for Optimizing T Cell Receptor Specificity Against Cancer
Hebeisen, M., Oberle, S. G., Presotto, D., Speiser, D. E., Zehn, D., & Rufer, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00154 · Cited by 45
“Curiously, HVEM also binds to BTLA and CD160, which are structurally similar to PD-1 and CTLA-4 and transduce inhibitory signals, in part through recruitment of SHP-1 and SHP-2 phosphatases (Watanabe et al., 2003; Sedy et al., 2005).”
BackgroundChung, J., Shiue, L. H., Duvic, M. A., Pandya, A. G., Cruz, P. D., & Ariizumi, K. (2011) · Blood · doi:10.1182/blood-2010-08-302034 · Cited by 40
Tang, Z., Hao, Y.-H., Zhang, E., Xu, C., Zhou, Y., Zheng, X., & Yang, D. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5396 · Cited by 39
“Previous studies demonstrated that, similar with PD-1 and CTLA-4, BTLA inhibits the activation of T cells, the initialization of CD4 + T cells, and the second reaction of CD4 + and CD8 + T cells (28,29).”
Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation
Parry, R. V., Riley, J. L., & Ward, S. G. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.02.004 · Cited by 43
Uchiyama, M., Jin, X., Matsuda, H., Bashuda, H., Imazuru, T., Shimokawa, T., Yagita∥, H., & Niimi, M. (2014) · Transplantation · doi:10.1097/01.tp.0000438204.96723.8b · Cited by 41
“Additionally, many experimental models indicated that targeting of co-inhibitory pathway including BTLA may potentially provide a novel approach to transplantation tolerance and also permit minimal immunosuppression (16, 20, 21).”
BackgroundLiu, J., Li, J., He, M. Y., Zhang, G.-L., & Zhao, Q. (2018) · Journal of Immunology Research · doi:10.1155/2018/4561571 · Cited by 38
The role of immune regulatory molecules in multiple sclerosis
Afshar, B., Khalifehzadeh-Esfahani, Z., Seyfizadeh, N., Danbaran, G. R., Hemmatzadeh, M., & Mohammadi, H. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577061 · Cited by 39
Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells
Occhipinti, S., Dianzani, C., Chiocchetti, A., Boggio, E. M., Clemente, N., Gigliotti, C. L., Soluri, M. F., Minelli, R., Fantozzi, R., Yagi, J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201816 · Cited by 38
del Rio, M., Kaye, J., & Rodríguez-Barbosa, J.-I. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.09.008 · Cited by 39
Hensler, E., Petros, H., Gray, C. C., Chung, C., Ayala, A., & Fallon, E. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940930 · Cited by 42
“BTLA is amember of the Ig superfamily of proteins and contains 2 ITIM domains (113).”
BackgroundImmune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 41
Nan, X.-P., Zhang, Y., Yu, H.-T., Li, Y., Sun, R.-L., Wang, J.-P., & Bai, X.-F. (2010) · Viral Immunology · doi:10.1089/vim.2009.0061 · Cited by 37
“BTLA-deficient mice showed evidence of an inhibitory role of BTLA in lymphocytes, based on increased antibody responses and heightened sensitivity to antigen-induced experimental allergic encephalomyelitis (37).”
Targeting of the immune system in systemic lupus erythematosus
Ramanujam, M., & Davidson, A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000562 · Cited by 40
Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
Song, J., & Wu, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00148 · Cited by 43
“B and T lymphocyte attenuator, CTLA-4, CD28, inducible costimulatory molecule (ICOS), and PD-1 are all belonging to the CD28 immunoglobulin superfamily (Ishida et al., 1992; Hutloff et al., 1999; Freeman et al., 2000; Watanabe et al., 2003).”
BackgroundInfluentialAhmad, I. M., Dafferner, A. J., O’Connell, K. A., Mehla, K., Britigan, B. E., Hollingsworth, M. A., & Abdalla, M. Y. (2021) · Cancers · doi:10.3390/cancers13092264 · Cited by 39
“B- and T-lymphocyte attenuator (BTLA) is an inhibitory receptor that shares structural and functional similarity with CTLA-4 and PD-1, and is expressed in T-lymphocytes [42,43].”
BackgroundImmunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Zhou, Y., Shu, Q., Fu, Z., Wang, C., Gu, J., Li, J., Chen, Y., & Xie, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.959456 · Cited by 42
“As a third inhibitory receptor on T lymphocytes, BTLA is related to PD-1 and CTLA-4 in terms of its structure and function (Watanabe et al., 2003; Fallon et al., 2018).”
BackgroundB and T Lymphocyte Attenuator Regulates T Cell Survival in the Lung
Deppong, C., Degnan, J. M., Murphy, T. L., Murphy, K. M., & Green, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.2973 · Cited by 36
“Depending on the system, both PD-1 and BTLA have been observed to have either stimulatory or inhibitory effects on T cell function (5, 6).”
BackgroundMethodSelf-citationSteinberg, M. W., Shui, J., Ware, C. F., & Kronenberg, M. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0157-4 · Cited by 37
“Although it shares relatively low sequence homology with the other proteins in this family [24], it is structurally most similar to the inhibitory B7 members, including the cytotoxic T-lymphocyte antigen-4 (CTLA-4 or CD152) and programmed death-1 (PD-1) [25].”
InfluentialGarapati, P. V., & Lefranc, M. (2007) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2007.01.008 · Cited by 37
“1 kb and comprises five exons (EX1–EX5) which encodes 289 aa [24] (Table 3).”
BackgroundInfluentialZhang, G. ‐., Zhou, H., Chen, Y. ‐., Ge, Y., Xie, F., Shi, Q., Ma, H., Fei, M., & Zhang, X. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00449.x · Cited by 37
Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer
Hajj, J. E., Reddy, S., Verma, N., Huang, E. H., & Kazmi, S. M. A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00927-2 · Cited by 39
“When bound to its ligand, HVEM (Herpes virus entry mediator), it recruits SHP-1 and SHP-2 protein tyrosine phosphatases, suppressing T-cell receptor activation [104, 105].”
Pitts, S. C., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03074-z · Cited by 39
Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies
Lloyd, A., Vickery, O. N., & Laugel, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00221 · Cited by 36
Potentiating cancer vaccine efficacy in liver cancer
Tagliamonte, M., Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1488564 · Cited by 36
Translation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 43
Truong, W., Hancock, W. W., Plester, J. C., Merani, S., Rayner, D. C., Thangavelu, G., MURPHY, K. M. M., Anderson, C. C., & Shapiro, A. M. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107753 · Cited by 36
Self-citationTNF family members and malaria: Old observations, new insights and future directions
Randall, L. M., & Engwerda, C. R. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2010.04.016 · Cited by 36
Cheng, T., Bai, J., Chung, C.-S., Chen, Y., Biron, B. M., & Ayala, A. (2016) · Shock · doi:10.1097/shk.0000000000000479 · Cited by 36
“BTLA has been shown to inhibit CD4þ T cell polarization into Th1 cells (42).”
BackgroundHerpesvirus Entry Mediator and Ocular Herpesvirus Infection: More than Meets the Eye
Mayhew, R. G. E., & Longnecker, R. (2017) · Journal of Virology · doi:10.1128/jvi.00115-17 · Cited by 38
“Flow cytometry of whole corneas from C57BL/6 mice indicates that the majority of HVEM is located on CD11b CD11c Ly6C Ly6G monocyte lineage cells in the acute phase and on PMN and CD4 T cells in the chronic phase (55).”
BackgroundInfluentialBreloer, M., Hartmann, W., Blankenhaus, B., Eschbach, M.-L., Pfeffer, K., & Jacobs, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402510 · Cited by 35
Zhou, F., Ćirić, B., Zhang, G., & Rostami, A. M. (2013) · Immunologic Research · doi:10.1007/s12026-012-8382-7 · Cited by 35
“APC Antigen-presenting cell BTLA B- and T-lymphocyte attenuator CTLA-4 Cytotoxic T-lymphocyte antigen-4 DC Dendritic cell EAE Experimental autoimmune encephalomyelitis FCS Fetal calf serum GM-CSF Granulocyte–macrophage colony-stimulating factor ICOS Inducible co-stimulator i.v Intravenous MOG Myelin oligodendrocyte gl…”
InfluentialOn the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function
Vanamee, É. S., & Faustman, D. L. (2020) · Cells · doi:10.3390/cells9030764 · Cited by 37
“BTLA is an immune-globulin superfamily (IgSF) glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs [46].”
BackgroundZhang, J., Lu, Y.-B., Wang, W., Liu, G.-B., Chen, C., Shen, L., Luo, H., Xu, H., Peng, Y., Luo, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00518 · Cited by 36
“The B and T lymphocyte attenuator (BTLA) is an inhibitory receptor and shares structural and functional similarities with cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) (16).”
BackgroundTLR2-mediated innate immune priming boosts lung anti-viral immunity
Girkin, J. L. N., Loo, S.-L., Esneau, C., Maltby, S., Mercuri, F. A., Chua, B. Y. L., Reid, A. T., Veerati, P. C., Grainge, C., Wark, P. A. B., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01584-2020 · Cited by 35
Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma
Li, G., Jiang, Y., Li, G., & Qiao, Q. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.03.017 · Cited by 38
Lebbink, R. J., & Meyaard, L. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.11.014 · Cited by 38
Smith, K. A., & Popmihajlov, Z. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00654.x · Cited by 35
“Watanabe N, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.”
BackgroundZhang, Z., Xu, X., Lu, J., Zhang, S., Gu, L., Fu, J., Jin, L., Li, H., Zhao, M., Zhang, J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir165 · Cited by 35
“ing that BTLA predominantly regulates immune responses negatively [24, 25].”
BackgroundYe, Z., Deng, B., Wang, C., Zhang, D., Kijlstra, A., & Yang, P. (2016) · Scientific Reports · doi:10.1038/srep20401 · Cited by 37
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo, O., Arina, A., Tirapu, I., Alfaro, C., Mazzolini, G. D., Palencia, B., de Cerio, A. L.-D., Prìeto, J., Bendandi, M., & Melero, I. (2003) · PubMed · Cited by 38
Shao, R., Li, C., Fang, Y., Zhao, L., & Hang, C. (2015) · Critical Care · doi:10.1186/s13054-015-1024-4 · Cited by 36
“BTLA is a recently characterized co-inhibitory molecule expressed on T cells, B cells, natural killer (NK) cells, macrophages and dendritic cells [7, 8].”
BackgroundKarabon, L., Partyka, A., Ciszak, L., Pawlak, E., Tomkiewicz, A., Bojarska-Junak, A. A., Roliński, J., Wołowiec, D., Wróbel, T., Frydecka, I., et al. (2020) · Journal of Immunology Research · doi:10.1155/2020/6545921 · Cited by 37
“BTLA-de fi cient T and B cells show enhanced proliferation in response to anti-CD3 and anti-IgM stimulation, respectively [11], while BTLA-de fi cient mice exhibit enhanced predisposition to autoimmunity [11].”
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Sheikholeslami, S. A., Salari, S., & Bashash, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103160 · Cited by 35
The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle
Masoumi, E., Tahaghoghi-Hajghorbani, S., Jafarzadeh, L., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.018 · Cited by 35
Ghorbaninezhad, F., Asadzadeh, Z., Masoumi, J., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Shadbad, M. A., Baghbanzadeh, A., Hemmat, N., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120466 · Cited by 39
SH2 Domain-Containing Protein-Tyrosine Phosphatases
Neel, B. G., Chan, G., & Dhanji, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00098-x · Cited by 37
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.
Loke, P., & Allison, J. P. (2004) · Arthritis Research · doi:10.1186/ar1225 · Cited by 37
“208 APC = antigen-presenting cell; BTLA = B and T lymphocyte attenuator; CTLA-4 = cytotoxic T lymphocyte-associated antigen-4; DC = dendritic cell; FOXP3 = forkhead box P3; GITR = glucocorticoid-induced tumor necrosis factor receptor; ICOS = inducible costimulatory molecule; IDO = indoleamine 2,3-dioxygenase; IL = int…”
BackgroundSelf-citationCD160 isoforms and regulation of CD4 and CD8 T-cell responses
Far, M. E., Pellerin, C., Pilote, L., Fortin, J.-F., Lessard, I. A. D., Peretz, Y., Wardrop, E., Salois, P., Bethell, R. C., Cordingley, M. G., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0217-y · Cited by 37
“Kojima R, Kajikawa M, Shiroishi M, Kuroki K, Maenaka K: Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.”
ResultInfluentialDouna, H., Amersfoort, J., Schaftenaar, F. H., Kröner, M. J., Kiss, M. G., Slütter, B., Depuydt, M. A. C., Kleijn, M. N. A. B., Wezel, A., Smeets, H. J., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz129 · Cited by 40
“Ligation of HVEM to BTLA generates an inhibitory signal, which is supported by the fact that BTLA-deficient T and B cells are hyperresponsive.(3,5,6) In addition, BTLA-deficient mice show a marked phenotype of auto-immunity with increased levels of auto-antibodies, spontaneous development of autoimmune-like hepatitis,…”
BackgroundMathematical Models and Immune Cell Biology
Molina-París, C., & Lythe, G. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0 · Cited by 43
Nelson, C. A., Fremont, M. D., Šedý, J. R., Norris, P. S., Ware, C. F., MURPHY, K. M. M., & Fremont, D. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.940 · Cited by 34
“by T cell hybridomas in response to anti-CD3 stimulation (11).”
BackgroundInfluentialSelf-citationThe quantal theory of how the immune system discriminates between "self and non-self"
Smith, K. A. (2004) · Medical Immunology · doi:10.1186/1476-9433-3-3 · Cited by 34
“Still a third, later appearing coinhibitory receptor, BTLA, has also recently been described as expressed on both antigen-activated T cells and B cells[128].”
BackgroundB and T Lymphocyte Attenuator Restricts the Protective Immune Response against Experimental Malaria
Adler, G., Steeg, C., Pfeffer, K., Murphy, T. L., Murphy, K. M., Langhorne, J., & Jacobs, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101456 · Cited by 33
“BTLA-KO mice are also more susceptible to experimental autoimmune encephalomyelitis (1) and Con A-induced hepatitis (13).”
BackgroundSelf-citationImmunotherapies: The Blockade of Inhibitory Signals
Wu, Y., Liang, J., Zhang, W., Tanaka, Y., & Sugiyama, H. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5273 · Cited by 35
“Identified initially as a molecule selectively expressed on Th1 cells, it is induced on T cells during activation and remains expressed more strongly on polarized Th1, not Th2 cells [84], implying that BTLA may specifically down-regulate Th1-mediated inflammatory responses [85].”
BackgroundThe Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity
Hsu, Y. O., Lu, K., Fu, Y., Wang, C., Lu, C., Lin, Y., Chang, W.-C., Yeh, K., Chung, W., Chung, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.597761 · Cited by 33
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 35
Li, L., & Boussiotis, V. A. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0098-5 · Cited by 41
“Indeed, T cell activation is enhanced in BTLA-deficient mice [31, 32].”
BackgroundIL-10 suppresses CD2-mediated T cell activation via SHP-1
Taylor, A., Verhagen, J., Akkoç, T., Wenig, R., Flory, E., Blaser, K., Akdiş, M., & Akdiş, C. A. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.07.031 · Cited by 32
Oya, Y., Watanabe, N., Kobayashi, Y., Owada, T., Oki, M., Ikeda, K., Suto, A., Kagami, S., Hirose, K., Kishimoto, T., et al. (2011) · International Immunology · doi:10.1093/intimm/dxr017 · Cited by 33
Self-citationProtective Roles of B and T Lymphocyte Attenuator in NKT Cell-Mediated Experimental Hepatitis
Iwata, A., Watanabe, N., Oya, Y., Owada, T., Ikeda, K., Suto, A., Kagami, S., Hirose, K., Kanari, H., Kawashima, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900389 · Cited by 31
“Initially, we have shown that the sensitivity to experimental autoimmune encephalomyelitis as well as T cell-dependent Ab responses is increased in BTLA mice (3).”
BackgroundMethodResultSelf-citation
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.